New drug combo targets advanced cancers in Mid-Stage trial
NCT ID NCT07130383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination is safe and can shrink tumors. About 210 adults aged 18 to 75 with measurable tumors and adequate organ function will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201419, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Oral drug elraglusib aims to tame advanced solid tumors
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- Engineered virus targets Hard-to-Treat cancers from the inside